CAR-T Goes In Vivo: A New Map of Analytical Instrument Demand 

CAR-T (Chimeric Antigen Receptor T-cell) therapy has emerged as one of the most consequential advances in immunotherapy. It’s a treatment designed to engage the body’s own immune system against disease. These therapies are reshaping how clinicians approach blood cancers and immune-related conditions that historically evade immune response or suppress it entirely. 

The mechanism depends on T-cells, the immune system’s primary threat-identification agents. T-cells tag foreign invaders for annihilation by macrophages. In CAR-T therapy, a patient’s T-cells are collected, genetically re-engineered to express a Chimeric Antigen Receptor (CAR), and returned to the body. That receptor enables the modified T-cells to recognize and bind to specific disease antigens. This flags cancer cells or misdirected immune cells as targets for macrophage-mediated destruction. The process essentially gives the immune system a new set of targeting instructions for threats it would otherwise miss. 

What This Means for the Instrumentation World Today 

The current standard of care, known as ex vivo CAR-T, is expensive, logistically intensive, and slow. A patient’s T-cells are harvested, then shipped to a centralized cGMP manufacturing facility where they are cultured, transduced with the CAR construct (typically using a lentiviral vector), expanded over several months, and processed into multiple treatment batches before being returned to the clinical site. Each step requires rigorous quality control. 

The analytical instrumentation supporting this workflow is substantial. The table below summarizes the primary RUO instrument categories SDi tracks across the ex vivo manufacturing and QC process. 

Instrument Category	Primary Use in Ex Vivo CAR-T	Example Vendors
Flow cytometry	T-cell phenotyping, CAR expression verification, transduction efficiency, viability, batch release	BD, Beckman Coulter, Cytek, Sony, Miltenyi
Mass spectrometry	Residual host cell protein analysis, vector protein characterization, potency assay development	Thermo Fisher, Waters, SCIEX, Agilent, Bruker
Chromatography (HPLC, UPLC)	Vector purity, residual reagent quantification, media component analysis	Agilent, Waters, Thermo Fisher, Shimadzu
qPCR and dPCR	Vector copy number, residual DNA, mycoplasma testing, viral titer	Bio-Rad, Thermo Fisher, Stilla, Qiagen
Optical and fluorescence microscopy	Cell morphology assessment, batch verification, transduction visualization	Leica, Zeiss, Nikon, Olympus
Cell counters and image cytometers	Cell count, viability, expansion monitoring across the manufacturing run	Revvity (Nexcelom), ChemoMetec, Logos, Beckman

Table 1. Representative SDi-covered RUO analytical instrumentation in the ex vivo CAR-T workflow. Vendor lists are illustrative, not exhaustive. 

Scientific instrumentation serves both QC and R&D functions in this workflow. However, the centralized, patient-specific nature of ex vivo manufacturing creates per-treatment costs that regularly exceed $400,000, limiting access and scalability. 

In Vivo CAR-T: The Concept and the Science 

Recent research has produced an alternative approach that bypasses ex vivo manufacturing entirely. Rather than removing a patient’s T-cells, engineering them externally, and reinfusing them, in vivo CAR-T delivers the genetic instructions directly into the patient through specialized lipid delivery mechanisms. Then, the body’s own T-cells take up the payload and become CAR-T cells that perform their intended targeted function. 

“In vivo CAR T cell generation to treat cancer and autoimmune disease.” by Theresa L. Hunter et al., Science, demonstrated that mRNA encoding a CAR construct could be delivered systemically, taken up by circulating T-cells, and produce meaningful therapeutic effects in vivo. 

Two delivery approaches are currently in clinical testing. Targeted lipid nanoparticles (tLNPs) use the same basic vehicle as COVID-19 mRNA vaccines but are decorated with antibodies that steer the payload toward specific T-cell populations. Immune-shielded lentiviral vectors perform gene transfer inside the body rather than in a manufacturing suite. In both cases, the patient’s T-cells take up the CAR transgene and become engineered effector cells in situ. The result is a therapy that can be administered like any other off-the-shelf biologic, without the months-long manufacturing lead time and cGMP logistics of the ex vivo approach. 

Why Nearly Every In Vivo CAR-T Target Is a B-Cell Disease 

Every in vivo CAR-T program currently in the clinic targets B-cell-related diseases. B-cell malignancies and autoimmune disorders include B-cell mediated conditions such as systemic lupus erythematosus, multiple sclerosis, and myasthenia gravis (Capstan Therapeutics’ CPTX2309), as well as multiple myeloma (AstraZeneca/EsoBiotec’s ESO-T01) and B-cell lymphomas (Interius BioTherapeutics’ INT2104 and Umoja Biopharma’s UB-VV111). 

As to why, you have to look at B cell and methods surrounding them. B cells carry well-characterized surface markers: CD19, CD20, and BCMA. These have deep clinical precedent from rituximab and the approved ex vivo CAR-T therapies (Kymriah, Yescarta, Carvykti). The biology is well understood, the assays for measuring B-cell depletion are mature, and a recovering naive B-cell compartment provides a relatively clean readout of therapeutic effect. Solid tumors, by contrast, present a substantially harder problem for in vivo delivery and are unlikely to be addressed at meaningful scale before 2030 at the earliest. 

The Clinical Landscape 

The first wave of in vivo CAR-T clinical trials is small but accelerating. Four programs represent the leading edge: 

CPTX2309 (Capstan Therapeutics): An anti-CD19 tLNP currently in Phase 1 healthy volunteer dosing in Australia for autoimmune indications. 

ESO-T01 (AstraZeneca/EsoBiotec): An anti-BCMA lentiviral vector for multiple myeloma. The first major Nature Medicine readout (March 2026) showed three of five stringent complete responses, with grade 3 or higher adverse events in all five patients. 

INT2104 (Interius BioTherapeutics): An anti-CD20 lentiviral vector for B-cell malignancies — notable as the first durable in vivo CAR cell therapy ever administered in the clinic, with the first patient dosed in late 2024. 

UB-VV111 (Umoja Biopharma/AbbVie): An anti-CD19 lentiviral vector cleared by the FDA in late 2024 for a US Phase 1. 

Patient numbers are small and safety profiles are still being established. The ESO-T01 cohort produced cytokine release syndrome in every patient, and one patient died from underlying disease progression rather than the therapy itself. But the principle of action has now been demonstrated in humans: targeted delivery vehicles can engineer CAR-T cells inside the body, those cells can deplete B cells, and they can produce real clinical responses. 

What This Means for the Instrumentation World Going Forward 

The in-vivo approach affords new opportunities for research demand Ex vivo CAR-T concentrated instrument purchasing at a relatively small number of GMP manufacturing sites and uses cell processing, viral vector production, and patient-batch QC instrument use. In vivo CAR-T offers and avenue for new demand by pushing it back into R&D, formulation development, and analytical characterization work that is more distributed across biopharma campuses, the CDMOs serving the LNP and lentivirus space, and the analytical CROs that support them. 

For the RUO analytical instrumentation that SDi tracks, the shift will be visible in both familiar and emerging categories: 

Mass spectrometry and chromatography remain heavily used in both variants, but for different analytes. For example, vector protein and residual reagents in ex vivo and mRNA payload integrity and ionizable lipid analysis in in vivo. 

Cryogenic electron microscopy (cryo-EM) moves from a relatively niche tool to a core characterization technique. LNP morphology and mRNA encapsulation efficiency are now critical quality attributes documented in regulatory filings. 

Confocal microscopy remains broadly applicable but takes on new specificity in biodistribution imaging and B-cell depletion verification. 

Atomic force microscopy and surface analyzers (XPS, ToF-SIMS) are seeing emerging interest in LNP elasticity and tLNP surface chemistry. Both are technically relevant to the new modality and both are currently under-represented in mainstream market analyses. 

The table below summarizes the dominant SDi-covered RUO instrument categories showing the strongest likely demand effects from in vivo CAR-T research and characterization workflows. 

Instrument Category	Primary Use in In Vivo CAR-T	Example Vendors
Mass spectrometry	LC-MS oligonucleotide mapping for mRNA primary structure, intact mRNA characterization, ionizable lipid identity and process impurities, lipidomics	Thermo Fisher (Orbitrap), Waters (BioAccord), SCIEX (ZenoTOF), Agilent, Bruker
Chromatography (CE, UPLC, HPLC-CAD)	mRNA integrity by CGE-LIF, encapsulation efficiency, capping and poly-A characterization, lipid component analysis	SCIEX (BioPhase 8800), Agilent (Fragment Analyzer), Waters, Thermo Fisher
Cryogenic electron microscopy	LNP morphology including bleb structure, mRNA payload encapsulation, lipid lamellarity, lentivirus particle integrity	Thermo Fisher (Glacios, Krios), JEOL (CRYO ARM)
Confocal microscopy	LNP cellular uptake imaging, T-cell transduction verification, B-cell depletion in tissue sections, CAR expression kinetics in live cells	Leica (Stellaris), Zeiss (LSM), Nikon (AX), Olympus (FV4000)
Super-resolution microscopy	LNP intracellular trafficking, endosomal escape mechanism work	Abberior, Bruker (Vutara), Nikon, Zeiss
Atomic force microscopy and SPM	LNP elasticity (Young’s modulus), surface topology, mechanical property mapping correlated to delivery efficiency	Bruker, Park Systems, JPK, Oxford Instruments
Surface analyzers (XPS, ToF-SIMS)	tLNP surface composition, PEG layer characterization, antibody conjugation verification	Thermo Fisher (Nexsa), Kratos, ION-TOF

Table 2. Representative SDi-covered RUO analytical instrumentation seeing the strongest demand pull from in vivo CAR-T research and characterization workflows. Vendor lists are illustrative, not exhaustive. 

The Bottom Line 

The strategic question for the OEM community is not whether in vivo CAR-T will displace ex vivo. We expect five-to-fifteen year horizon if technologies prove feasiable and the instrument demand attached to even the current cohort of clinical programs is already visible. The real question is whether a given vendor’s portfolio captures the redistribution of demand  or whether it sits on the wrong side of that shift. 

Mass spectrometry, chromatography, and cryo-EM are the clearest beneficiaries in this transition. AFM, super-resolution microscopy, and surface analyzers are smaller but credible growth pockets that are currently underweighted relative to their technical relevance. For analysts and OEMs tracking this market, the next two years of clinical readouts from Capstan, Interius, Umoja, AstraZeneca, and Sana will be the key indicator of whether this trajectory accelerates or stalls. 

Follow SDi to stay ahead of demand shifts across the analytical instrument market. 

About SDi 

SDi provides market intelligence for OEMs and suppliers serving the global analytical and life science instrument markets. Our research covers instrument demand trends, competitive landscapes, end-user spending patterns, and technology adoption across academic, biopharma, biotech, and industrial laboratory segments. Contact us to learn more about our subscription research and custom advisory services.